This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A single arm, open-label trial assessing the effec...
Clinical trial

A single arm, open-label trial assessing the effect of Capecitabine (Xeloda�) on progression-free survival rate at four months in breast cancer patients with CNS progression after whole brain radiotherapy

Read time: 1 mins
Last updated:7th Jul 2009
To evaluate the efficacy of capecitabine in terms of Progression Free Survival (PFS) rate at 4 months, reviewed by centralized independent expert, in treatment of brain metastases secondary to breast cancer in patients with CNS progression after whole brain radiotherapy (WBRT).
Category Value
Study start date 2009-07-07

View full details